View Financial HealthGlaxoSmithKlineE 배당 및 자사주 매입배당 기준 점검 2/6GlaxoSmithKlineE 수익으로 충분히 충당되는 현재 수익률 1.39% 보유한 배당금 지급 회사입니다.핵심 정보1.4%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률8.4%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향39%최근 배당 및 자사주 매입 업데이트공시 • Dec 31GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026GlaxoSmithKline S.A.E announced Annual dividend of EGP 1.0000 per share payable on January 14, 2026, ex-date on January 12, 2026 and record date on January 13, 2026.Upcoming Dividend • Jul 11Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 18 July 2024. Payment date: 22 July 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.6%. Lower than top quartile of Egyptian dividend payers (7.2%). Lower than average of industry peers (3.1%).Upcoming Dividend • Jun 27Upcoming dividend of ج.م0.75 per share at 2.3% yieldEligible shareholders must have bought the stock before 04 July 2023. Payment date: 06 July 2023. Trailing yield: 2.3%. Lower than top quartile of Egyptian dividend payers (7.6%). Lower than average of industry peers (3.6%).Upcoming Dividend • Dec 28Upcoming dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 04 January 2023. Payment date: 08 January 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.8%).Upcoming Dividend • Sep 13Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 20 September 2022. Payment date: 22 September 2022. Trailing yield: 2.1%. Lower than top quartile of Egyptian dividend payers (10%). Lower than average of industry peers (4.1%).Upcoming Dividend • Jun 28Upcoming dividend of ج.م0.50 per shareEligible shareholders must have bought the stock before 05 July 2021. Payment date: 07 July 2021. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.2%).모든 업데이트 보기Recent updatesBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Apr 11GlaxoSmithKline S.A.E, Annual General Meeting, May 03, 2026GlaxoSmithKline S.A.E, Annual General Meeting, May 03, 2026, at 15:30 Egypt Standard Time. Location: cairo Egypt공시 • Dec 31GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026GlaxoSmithKline S.A.E announced Annual dividend of EGP 1.0000 per share payable on January 14, 2026, ex-date on January 12, 2026 and record date on January 13, 2026.Reported Earnings • May 15First quarter 2025 earnings released: EPS: ج.م0.71 (vs ج.م0.11 loss in 1Q 2024)First quarter 2025 results: EPS: ج.م0.71 (up from ج.م0.11 loss in 1Q 2024). Revenue: ج.م993.9m (up 39% from 1Q 2024). Net income: ج.م59.1m (up ج.م68.1m from 1Q 2024). Profit margin: 5.9% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year and the company’s share price has also increased by 16% per year.Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • May 06GlaxoSmithKline S.A.E, Annual General Meeting, May 28, 2025GlaxoSmithKline S.A.E, Annual General Meeting, May 28, 2025, at 15:00 Egypt Standard Time. Location: cairo EgyptReported Earnings • Nov 16Third quarter 2024 earnings released: EPS: ج.م0.16 (vs ج.م0.33 in 3Q 2023)Third quarter 2024 results: EPS: ج.م0.16 (down from ج.م0.33 in 3Q 2023). Revenue: ج.م787.1m (up 37% from 3Q 2023). Net income: ج.م13.3m (down 51% from 3Q 2023). Profit margin: 1.7% (down from 4.7% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ج.م45.80, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 104% over the past three years.Valuation Update With 7 Day Price Move • Sep 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م36.23, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 50% over the past three years.Reported Earnings • Aug 18Second quarter 2024 earnings released: EPS: ج.م1.22 (vs ج.م0.07 in 2Q 2023)Second quarter 2024 results: EPS: ج.م1.22 (up from ج.م0.07 in 2Q 2023). Revenue: ج.م642.4m (up 19% from 2Q 2023). Net income: ج.م101.5m (up ج.م95.8m from 2Q 2023). Profit margin: 16% (up from 1.1% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 7% per year.Upcoming Dividend • Jul 11Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 18 July 2024. Payment date: 22 July 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.6%. Lower than top quartile of Egyptian dividend payers (7.2%). Lower than average of industry peers (3.1%).Reported Earnings • May 18First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ج.م713.8m (up 55% from 1Q 2023). Net loss: ج.م8.99m (down 165% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.New Risk • May 03New major risk - Revenue and earnings growthEarnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (ج.م2.60b market cap, or US$54.1m).New Risk • Apr 28New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (ج.م2.58b market cap, or US$53.9m).Valuation Update With 7 Day Price Move • Mar 18Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ج.م29.32, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 9x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 29% over the past three years.Reported Earnings • Mar 07Full year 2023 earnings releasedFull year 2023 results: Revenue: ج.م2.24b (up 23% from FY 2022). Net income: ج.م74.1m (up ج.م205.1m from FY 2022). Profit margin: 3.3% (up from net loss in FY 2022).Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م42.66, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 10x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 40% over the past three years.New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (ج.م2.95b market cap, or US$95.3m).New Risk • Aug 30New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risk Market cap is less than US$100m (ج.م2.61b market cap, or US$84.4m).Upcoming Dividend • Jun 27Upcoming dividend of ج.م0.75 per share at 2.3% yieldEligible shareholders must have bought the stock before 04 July 2023. Payment date: 06 July 2023. Trailing yield: 2.3%. Lower than top quartile of Egyptian dividend payers (7.6%). Lower than average of industry peers (3.6%).Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ج.م37.45, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 376% over the past three years.Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ج.م28.01, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 362% over the past three years.Upcoming Dividend • Dec 28Upcoming dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 04 January 2023. Payment date: 08 January 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.8%).Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ج.م35.37, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 93% over the past three years.Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improved over the past weekAfter last week's 22% share price gain to ج.م29.39, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 4x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 61% over the past three years.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Sep 13Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 20 September 2022. Payment date: 22 September 2022. Trailing yield: 2.1%. Lower than top quartile of Egyptian dividend payers (10%). Lower than average of industry peers (4.1%).Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Feb 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ج.م23.33, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total loss to shareholders of 38% over the past year.Valuation Update With 7 Day Price Move • Nov 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م20.08, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 6.1% over the past three years.Valuation Update With 7 Day Price Move • Oct 20Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م23.90, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 44% over the past year.Upcoming Dividend • Jun 28Upcoming dividend of ج.م0.50 per shareEligible shareholders must have bought the stock before 05 July 2021. Payment date: 07 July 2021. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.2%).공시 • Mar 12Hikma Pharmaceuticals PLC (LSE:HIK) cancelled the acquisition of GlaxoSmithKline S.A.E (CASE:BIOC).Hikma Pharmaceuticals PLC (LSE:HIK) entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E (CASE:BIOC) from Glaxo Group Limited on January 25, 2021. The transaction would be subject to satisfaction of certain conditions, including but not limited to (i) the completion of satisfactory due diligence, (ii) the entry into definitive and binding legal documents; and (iii) obtaining the approval(s) of the regulatory authorities. As of January 27, 2021, The board of directors of GlaxoSmithKline S.A.E agreed to allow Hikma Pharmaceuticals Plc to conduct due diligence. Hikma Pharmaceuticals PLC (LSE:HIK) cancelled the acquisition of GlaxoSmithKline S.A.E (CASE:BIOC) on March 11, 2021.공시 • Feb 02Glaxo Group Receives Letter from ACDIMA for Acquisition of Glaxosmithkline SharesGlaxo Group Limited received letter from Acdima - Arab Co. For Drugs Industries & Medical Appliances expressing interest in positioning an offer for potential acquisition of shares of majority shareholder in GlaxoSmithKline S.A.E (CASE:BIOC).Valuation Update With 7 Day Price Move • Jan 28Investor sentiment improved over the past weekAfter last week's 29% share price gain to ج.م21.28, the stock is trading at a trailing P/E ratio of 8.2x, up from the previous P/E ratio of 6.4x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total return to shareholders over the past three years is a loss of 9.7%.Is New 90 Day High Low • Jan 27New 90-day high: ج.م19.35The company is up 24% from its price of ج.م15.59 on 28 October 2020. The Egyptian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period.Is New 90 Day High Low • Dec 21New 90-day low: ج.م15.15The company is down 1.0% from its price of ج.م15.35 on 22 September 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.Reported Earnings • Nov 17Third quarter 2020 earnings released: ج.م0.17 loss per shareThe company reported a soft third quarter result with weaker earnings and control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: ج.م483.6m (up 12% from 3Q 2019). Net loss: ج.م14.6m (down 138% from profit in 3Q 2019).Is New 90 Day High Low • Nov 02New 90-day low: ج.م15.22The company is down 11% from its price of ج.م17.06 on 04 August 2020. The Egyptian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 04New 90-day high: ج.م18.34The company is up 9.0% from its price of ج.م16.82 on 06 July 2020. The Egyptian market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 8.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 배당금 지급이 안정적인 반면, BIOC 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.배당금 증가: BIOC 의 배당금 지급이 증가했지만 회사는 9 년 동안만 배당금을 지급했습니다.배당 수익률 vs 시장GlaxoSmithKlineE 배당 수익률 vs 시장BIOC의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BIOC)1.4%시장 하위 25% (EG)1.2%시장 상위 25% (EG)6.0%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (BIOC) (최대 3년)n/a주목할만한 배당금: BIOC 의 배당금( 1.39% )은 EG 시장에서 배당금 지급자의 하위 25%( 1.15% )보다 높습니다.고배당: BIOC 의 배당금( 1.39% )은 EG 시장에서 배당금 지급자의 상위 25%( 6.04% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적으로 낮은 지불 비율 ( 39.2% )로 BIOC 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 131.4% )이 높기 때문에 BIOC 의 배당금 지급은 현금 흐름으로 잘 충당되지 않습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YEG 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/07 13:01종가2026/07/07 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스GlaxoSmithKline S.A.E는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Dec 31GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026GlaxoSmithKline S.A.E announced Annual dividend of EGP 1.0000 per share payable on January 14, 2026, ex-date on January 12, 2026 and record date on January 13, 2026.
Upcoming Dividend • Jul 11Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 18 July 2024. Payment date: 22 July 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.6%. Lower than top quartile of Egyptian dividend payers (7.2%). Lower than average of industry peers (3.1%).
Upcoming Dividend • Jun 27Upcoming dividend of ج.م0.75 per share at 2.3% yieldEligible shareholders must have bought the stock before 04 July 2023. Payment date: 06 July 2023. Trailing yield: 2.3%. Lower than top quartile of Egyptian dividend payers (7.6%). Lower than average of industry peers (3.6%).
Upcoming Dividend • Dec 28Upcoming dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 04 January 2023. Payment date: 08 January 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.8%).
Upcoming Dividend • Sep 13Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 20 September 2022. Payment date: 22 September 2022. Trailing yield: 2.1%. Lower than top quartile of Egyptian dividend payers (10%). Lower than average of industry peers (4.1%).
Upcoming Dividend • Jun 28Upcoming dividend of ج.م0.50 per shareEligible shareholders must have bought the stock before 05 July 2021. Payment date: 07 July 2021. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.2%).
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Apr 11GlaxoSmithKline S.A.E, Annual General Meeting, May 03, 2026GlaxoSmithKline S.A.E, Annual General Meeting, May 03, 2026, at 15:30 Egypt Standard Time. Location: cairo Egypt
공시 • Dec 31GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026GlaxoSmithKline S.A.E announced Annual dividend of EGP 1.0000 per share payable on January 14, 2026, ex-date on January 12, 2026 and record date on January 13, 2026.
Reported Earnings • May 15First quarter 2025 earnings released: EPS: ج.م0.71 (vs ج.م0.11 loss in 1Q 2024)First quarter 2025 results: EPS: ج.م0.71 (up from ج.م0.11 loss in 1Q 2024). Revenue: ج.م993.9m (up 39% from 1Q 2024). Net income: ج.م59.1m (up ج.م68.1m from 1Q 2024). Profit margin: 5.9% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year and the company’s share price has also increased by 16% per year.
Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • May 06GlaxoSmithKline S.A.E, Annual General Meeting, May 28, 2025GlaxoSmithKline S.A.E, Annual General Meeting, May 28, 2025, at 15:00 Egypt Standard Time. Location: cairo Egypt
Reported Earnings • Nov 16Third quarter 2024 earnings released: EPS: ج.م0.16 (vs ج.م0.33 in 3Q 2023)Third quarter 2024 results: EPS: ج.م0.16 (down from ج.م0.33 in 3Q 2023). Revenue: ج.م787.1m (up 37% from 3Q 2023). Net income: ج.م13.3m (down 51% from 3Q 2023). Profit margin: 1.7% (down from 4.7% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ج.م45.80, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 104% over the past three years.
Valuation Update With 7 Day Price Move • Sep 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م36.23, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 50% over the past three years.
Reported Earnings • Aug 18Second quarter 2024 earnings released: EPS: ج.م1.22 (vs ج.م0.07 in 2Q 2023)Second quarter 2024 results: EPS: ج.م1.22 (up from ج.م0.07 in 2Q 2023). Revenue: ج.م642.4m (up 19% from 2Q 2023). Net income: ج.م101.5m (up ج.م95.8m from 2Q 2023). Profit margin: 16% (up from 1.1% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 7% per year.
Upcoming Dividend • Jul 11Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 18 July 2024. Payment date: 22 July 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.6%. Lower than top quartile of Egyptian dividend payers (7.2%). Lower than average of industry peers (3.1%).
Reported Earnings • May 18First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ج.م713.8m (up 55% from 1Q 2023). Net loss: ج.م8.99m (down 165% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
New Risk • May 03New major risk - Revenue and earnings growthEarnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (ج.م2.60b market cap, or US$54.1m).
New Risk • Apr 28New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (ج.م2.58b market cap, or US$53.9m).
Valuation Update With 7 Day Price Move • Mar 18Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ج.م29.32, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 9x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 29% over the past three years.
Reported Earnings • Mar 07Full year 2023 earnings releasedFull year 2023 results: Revenue: ج.م2.24b (up 23% from FY 2022). Net income: ج.م74.1m (up ج.م205.1m from FY 2022). Profit margin: 3.3% (up from net loss in FY 2022).
Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م42.66, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 10x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 40% over the past three years.
New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (ج.م2.95b market cap, or US$95.3m).
New Risk • Aug 30New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risk Market cap is less than US$100m (ج.م2.61b market cap, or US$84.4m).
Upcoming Dividend • Jun 27Upcoming dividend of ج.م0.75 per share at 2.3% yieldEligible shareholders must have bought the stock before 04 July 2023. Payment date: 06 July 2023. Trailing yield: 2.3%. Lower than top quartile of Egyptian dividend payers (7.6%). Lower than average of industry peers (3.6%).
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ج.م37.45, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 376% over the past three years.
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ج.م28.01, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 362% over the past three years.
Upcoming Dividend • Dec 28Upcoming dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 04 January 2023. Payment date: 08 January 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.8%).
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ج.م35.37, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 93% over the past three years.
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improved over the past weekAfter last week's 22% share price gain to ج.م29.39, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 4x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 61% over the past three years.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Sep 13Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 20 September 2022. Payment date: 22 September 2022. Trailing yield: 2.1%. Lower than top quartile of Egyptian dividend payers (10%). Lower than average of industry peers (4.1%).
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Feb 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ج.م23.33, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total loss to shareholders of 38% over the past year.
Valuation Update With 7 Day Price Move • Nov 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م20.08, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 6.1% over the past three years.
Valuation Update With 7 Day Price Move • Oct 20Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م23.90, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 44% over the past year.
Upcoming Dividend • Jun 28Upcoming dividend of ج.م0.50 per shareEligible shareholders must have bought the stock before 05 July 2021. Payment date: 07 July 2021. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.2%).
공시 • Mar 12Hikma Pharmaceuticals PLC (LSE:HIK) cancelled the acquisition of GlaxoSmithKline S.A.E (CASE:BIOC).Hikma Pharmaceuticals PLC (LSE:HIK) entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E (CASE:BIOC) from Glaxo Group Limited on January 25, 2021. The transaction would be subject to satisfaction of certain conditions, including but not limited to (i) the completion of satisfactory due diligence, (ii) the entry into definitive and binding legal documents; and (iii) obtaining the approval(s) of the regulatory authorities. As of January 27, 2021, The board of directors of GlaxoSmithKline S.A.E agreed to allow Hikma Pharmaceuticals Plc to conduct due diligence. Hikma Pharmaceuticals PLC (LSE:HIK) cancelled the acquisition of GlaxoSmithKline S.A.E (CASE:BIOC) on March 11, 2021.
공시 • Feb 02Glaxo Group Receives Letter from ACDIMA for Acquisition of Glaxosmithkline SharesGlaxo Group Limited received letter from Acdima - Arab Co. For Drugs Industries & Medical Appliances expressing interest in positioning an offer for potential acquisition of shares of majority shareholder in GlaxoSmithKline S.A.E (CASE:BIOC).
Valuation Update With 7 Day Price Move • Jan 28Investor sentiment improved over the past weekAfter last week's 29% share price gain to ج.م21.28, the stock is trading at a trailing P/E ratio of 8.2x, up from the previous P/E ratio of 6.4x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total return to shareholders over the past three years is a loss of 9.7%.
Is New 90 Day High Low • Jan 27New 90-day high: ج.م19.35The company is up 24% from its price of ج.م15.59 on 28 October 2020. The Egyptian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Dec 21New 90-day low: ج.م15.15The company is down 1.0% from its price of ج.م15.35 on 22 September 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
Reported Earnings • Nov 17Third quarter 2020 earnings released: ج.م0.17 loss per shareThe company reported a soft third quarter result with weaker earnings and control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: ج.م483.6m (up 12% from 3Q 2019). Net loss: ج.م14.6m (down 138% from profit in 3Q 2019).
Is New 90 Day High Low • Nov 02New 90-day low: ج.م15.22The company is down 11% from its price of ج.م17.06 on 04 August 2020. The Egyptian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 04New 90-day high: ج.م18.34The company is up 9.0% from its price of ج.م16.82 on 06 July 2020. The Egyptian market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 8.0% over the same period.